CTRI/2023/09/058102招募中Unknown
SPADE – aSia Pacific Avelumab blaDder cancer maintEnance - SPADE
Merck Pte Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Adult patients, aged greater or equal to 18 years of age (or per country’s legal adult age) at the time of signing the informed consent form(ICF)
- •2. Patients with unresectable local advanced or metastatic UC with measurable stage IV disease regardless of histology 3. Patients who have completed 1L platinum-based chemotherapy with no evidence of disease progression 4. Patients planned to receive avelumab as the 1L maintenance therapy according to country’s approved drug label
- •5. Patients who have provided written informed consent to participate in this study
排除标准
- •1. Patients with contraindications for avelumab according to the country’s approved drug label
- •2. Patients who have participated in any interventional clinical trial of a drug or device within the 28 days prior to the start of avelumab maintenance therapy
研究者
相似试验
招募中
1 期
Personalized medicine for advanced biliary cancer patientsCTIS2023-508100-38-00nicancer559
进行中(未招募)
3 期
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingJPRN-jRCT2031210487Kawai Norisuke262
进行中(未招募)
不适用
MAINTENANCE TREATMENT WITH ALEMTUZUMAB Campath AS AN ALTERNATIVE TO ALLOGENIC TRANSPLANTATION IN PATIENTS WITHOUT COMPATIBLE DONOR IN PATIENTS WITH PERIPHERAL T CELL LYMPHOMA - NDpatients with Perpheral T cell LymphomaMedDRA version: 6.1Level: HLGTClassification code 10025321EUCTR2006-001164-24-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI25
已完成
不适用
Prevalence of Non Communicable Disease study- Indian rural populatioCTRI/2018/08/015376Kovai Medical Center and Hospital865
已完成
2 期
TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancerColorectal CancerJPRN-UMIN000031790Surgical Oncology Association in Chiba (SOAC)45
